Navigation Links
Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
Date:6/16/2008

lated to quinolones, a class of compounds which has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, irreversible G2 arrest and rapid apoptosis. Voreloxin is currently being evaluated as a single agent in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients, in a Phase 1b clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, and as a single agent in a Phase 2 clinical trial in platinum-resistant ovarian cancer. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.

About Acute Myeloid Leukemia

AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the development of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
2. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
3. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
4. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
5. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
9. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
10. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
11. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... China Nepstar Chain Drugstore Ltd. (NYSE: ... leading retail drugstore chain in China based on ... its unaudited financial results for the second quarter ... quarter ended June 30, 2014: , Revenue increased ... RMB638.8 million in the second quarter of 2013 ...
(Date:8/27/2014)... 2014 TWi Pharmaceuticals, Inc. (4180.TT) today announced ... United States Food and Drug Administration (FDA) on ... acetate 125mg/ml oral suspension, the generic equivalent to ... and under Hatch Waxman rules, it will be ... has completed the pre-launch preparation of the generic ...
(Date:8/27/2014)... , Aug. 27, 2014 ... report: Collaborative R&D Terms & ... https://www.reportbuyer.com/product/2276220/Collaborative-RD-Terms--Agreements-in-Pharma-Biotech-and-Diagnostics.html The Collaborative ... and Diagnostics report provides comprehensive understanding and ... and agreements entered into by the worlds ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 11TWi Pharmaceuticals Receives US FDA Final Approval on Generic Megestrol Acetate 125mg/ml Oral Suspension 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 4Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 5Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 6Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 7Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 8Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 9
... ACCESS PHARMACEUTICALS, INC. (OTC Bulletin ... thiarabine shows remarkable efficacy in the prevention and treatment of rheumatoid ... restoration of joint structure was observed in the studies, which were ... at Southern Research Institute. , , As a therapeutic ...
... REDWOOD CITY, Calif., July 7 Relievant Medsystems, Inc., ... low back pain, reported today that it has completed ... was led by Morgenthaler Ventures with existing investors Canaan ... Partners participating. The company also announced that Morgenthaler ...
Cached Medicine Technology:Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis 2Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis 3Relievant Medsystems Announces Completion of $20 Million Financing 2Relievant Medsystems Announces Completion of $20 Million Financing 3
(Date:8/28/2014)... August 28, 2014 Top 10 ... web hosting companies and announces Bluehost, HostMonster ( ... suppliers for the webmasters worldwide who want to ... , As the world’s most popular server-side scripting ... many other general-purpose programs. It is now installed ...
(Date:8/28/2014)... ChiLiving® will host its inaugural ... at holistic retreat center, Om Sanctuary. This active ... and Danny Dreyer, offers beginner to seasoned runners ... support a lifetime of pain-free, injury-free movement in ... the heart of the Blue Ridge Mountains during ...
(Date:8/28/2014)... 28, 2014 Now in its 4th year, ... started in 2011 by two brain aneurysm survivors. The ongoing ... awareness, provide education to help increase early detection and to ... a brain aneurysm. We hope that you will be able ... at the 4th Annual Step for Hope Run/ Walk on ...
(Date:8/28/2014)... Alpine, NJ resident Othon Mourkakos is ... Zebras In Tiaras, to benefit the Immune Deficiency Foundation ... 26, 2014 in Foley Square, New York. IDF ... immunodeficiency diseases (PI) are a group of more than ... the body’s immune system is missing or functions improperly. ...
(Date:8/28/2014)... Livermore, CA (PRWEB) August 28, 2014 ... newest California physician, James Patel M.D. of Livermore, California. ... the best and most qualified physicians, and in accordance ... and our patients to Dr. Patel’s practice. , Initially ... at a young age, Dr. Patel was shaped by ...
Breaking Medicine News(10 mins):Health News:Join ChiRunning® & ChiWalking® Creators, Katherine and Danny Dreyer, for First-ever ChiWeekend Retreat in Asheville, NC 2Health News:Join ChiRunning® & ChiWalking® Creators, Katherine and Danny Dreyer, for First-ever ChiWeekend Retreat in Asheville, NC 3Health News:Step for Hope and Raise Brain Aneurysm Awareness 2Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 2Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 3Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 4
... which comes from the foxglove plant, is normally used to ... the heart and treat heart diseases. The chemical nature of ... University of Wisconsin-Madison to make the drug fight against cancer//., ... works by changing the sugars attached to the drug. By ...
... According to a latest study researchers say health professionals ... manage the risks associated with over the counter drugs. ... one of the most common condition that people choose ... of the other commonly treated ailments include heartburn, migraine, ...
... stutent multi-kinase inhibitors against cancer is undergoing phase 3 ... this years ASCO (American Society of Clinical Oncology) conference. ... mechanism of action – known as Multi-kinase inhibitors. These ... and are found to be very effective. This two ...
... two different types of low fat, low cholesterol diets researchers ... diet consisting of lean meats and other low fat foods ... percent. However, those who consumed a diet rich in plant-based ... as well, lowering their LDL levels by about 9.4 percent. ...
... Researchers say Kelp seaweed may be the next food ... findings from an animal study conducted at the University ... the seaweed effectively reduced levels of estradiol, // a ... rats. The rats also experienced a lengthening of their ...
... say an indirect CT venography ( CTV ) could identify ... break free, travel to the lung, and block an artery ... arteries are not visible in a commonly used lung scan, ... presence of these blood clots in the lung. ...
Cached Medicine News:
A system with integrated pupil camera and 7" examination monitor. An easy to use configuration....
The only air-based esthesiometer with a database of normal sensation on the cornea. May have application to the measurement of normal-tension glaucoma....
Produce clean 0.75 mm round hole without tissue tags. Serrated squeeze action handle....
Brightness acuity tester....
Medicine Products: